Long-term benefit of first-line peri-implantable cardioverter–defibrillator implant ventricular tachycardia-substrate ablation in secondary prevention patients
EP Europace Journal

Abstract
This study assessed the benefit of peri-implantable cardioverter–defibrillator implant ventricular tachycardia (VT)-substrate ablation in patients with structural heart disease (SHD).
Patients with SHD and indication for secondary prevention ICD implant were prospectively included. Patients presenting with incessant and/or slow VT or frequent (≥2) VT episodes who underwent peri-ICD VT-substrate ablation (the scar dechannelling technique) were compared with those who received ICD alone and did not meet ablation criteria. The primary endpoint was any sustained VT/ICD therapy during follow-up. Of 206 patients included (43.2% non-ischaemic), 70 were assigned to ablation and 136 received ICD implant alone. During a mean follow-up of 45.6 ± 24.7 months, the primary endpoint was more frequent in the non-ablation group (47.1 vs. 22.9%;
First-line peri-ICD implant VT-substrate ablation was associated with decreased VT recurrence and ICD shocks during long-term follow-up in patients with SHD and indication for secondary prevention ICD implant, especially in ischaemic patients. In patients with LVEF <35%, no benefit was observed in terms of VT recurrence-free survival, although VT burden during follow-up was lower in the ablation group.
Contributors

Juan Acosta
Author

Nuno Cabanelas
Author

Diego Penela
Author

Juan Fernández-Armenta
Author

David Andreu
Author

Roger Borràs
Author

Viatcheslav Korshunov
Author

Mario Cabrera
Author

Francesca Vasanelli
Author

Elena Arbelo
Author

Eduard Guasch
Author

Mikel Martínez
Author

Jose M. Tolosana
Author

Lluis Mont
Author

Antonio Berruezo
Author
